162 related articles for article (PubMed ID: 31111038)
1. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors.
Miller J; Campbell J; Blum A; Reddell P; Gordon V; Schmidt P; Lowden S
Front Vet Sci; 2019; 6():106. PubMed ID: 31111038
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).
Panizza BJ; de Souza P; Cooper A; Roohullah A; Karapetis CS; Lickliter JD
EBioMedicine; 2019 Dec; 50():433-441. PubMed ID: 31810818
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).
De Ridder TR; Campbell JE; Burke-Schwarz C; Clegg D; Elliot EL; Geller S; Kozak W; Pittenger ST; Pruitt JB; Riehl J; White J; Wiest ML; Johannes CM; Morton J; Jones PD; Schmidt PF; Gordon V; Reddell P
J Vet Intern Med; 2021 Jan; 35(1):415-429. PubMed ID: 32542733
[TBL] [Abstract][Full Text] [Related]
4. Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate.
Brown GK; Campbell JE; Jones PD; De Ridder TR; Reddell P; Johannes CM
Front Vet Sci; 2021; 8():675804. PubMed ID: 34513966
[TBL] [Abstract][Full Text] [Related]
5. Use of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses.
De Ridder T; Ruppin M; Wheeless M; Williams S; Reddell P
Front Vet Sci; 2020; 7():639. PubMed ID: 33033726
[TBL] [Abstract][Full Text] [Related]
6. Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.
Jones PD; Campbell JE; Brown G; Johannes CM; Reddell P
J Vet Intern Med; 2021 Jan; 35(1):451-455. PubMed ID: 33350511
[TBL] [Abstract][Full Text] [Related]
7. Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.
Brown GK; Finlay JR; Straw RC; Ziea JY; Leung B; O'Connell K; Thomson MJ; Campbell JE; Jones PD; Reddell P
Front Vet Sci; 2022; 9():1003165. PubMed ID: 36387404
[TBL] [Abstract][Full Text] [Related]
8. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate.
Reddell P; De Ridder TR; Morton JM; Jones PD; Campbell JE; Brown G; Johannes CM; Schmidt PF; Gordon V
J Vet Intern Med; 2021 Jan; 35(1):430-441. PubMed ID: 33438258
[TBL] [Abstract][Full Text] [Related]
9. [Successful local treatment of a digital canine mast cell tumour with Tigilanol Tiglate].
Gasser K
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2022 Jun; 50(3):225-231. PubMed ID: 35790169
[TBL] [Abstract][Full Text] [Related]
10. Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours.
De Ridder T; Reddell P; Jones P; Brown G; Campbell J
Front Vet Sci; 2021; 8():764800. PubMed ID: 34977208
[TBL] [Abstract][Full Text] [Related]
11. Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate.
Barnett CME; Broit N; Yap PY; Cullen JK; Parsons PG; Panizza BJ; Boyle GM
Invest New Drugs; 2019 Feb; 37(1):1-8. PubMed ID: 29667135
[TBL] [Abstract][Full Text] [Related]
12. Progressive cutaneous viral pigmented plaques in three Hungarian Vizslas and the response of lesions to topical tigilanol tiglate gel.
Hansen N; Nicholas N; Pack G; Mackie JT; Shipstone M; Munday JS; Reddell P; Orbell G; Malik R
Vet Med Sci; 2018 Feb; 4(1):53-62. PubMed ID: 29468081
[TBL] [Abstract][Full Text] [Related]
13. Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes.
Cullen JK; Boyle GM; Yap PY; Elmlinger S; Simmons JL; Broit N; Johns J; Ferguson B; Maslovskaya LA; Savchenko AI; Mirzayans PM; Porzelle A; Bernhardt PV; Gordon VA; Reddell PW; Pagani A; Appendino G; Parsons PG; Williams CM
Sci Rep; 2021 Jan; 11(1):207. PubMed ID: 33420238
[TBL] [Abstract][Full Text] [Related]
14. Identification of Gene Biomarkers for Tigilanol Tiglate Content in
Mitu SA; Stewart P; Tran TD; Reddell PW; Cummins SF; Ogbourne SM
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807225
[TBL] [Abstract][Full Text] [Related]
15. Practical synthesis of the therapeutic leads tigilanol tiglate and its analogues.
Wender PA; Gentry ZO; Fanelli DJ; Luu-Nguyen QH; McAteer OD; Njoo E
Nat Chem; 2022 Dec; 14(12):1421-1426. PubMed ID: 36192432
[TBL] [Abstract][Full Text] [Related]
16. CD25 is expressed by canine cutaneous mast cell tumors but not by cutaneous connective tissue mast cells.
Meyer A; Gruber AD; Klopfleisch R
Vet Pathol; 2012 Nov; 49(6):988-97. PubMed ID: 22446323
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells.
Matsuda A; Tanaka A; Amagai Y; Ohmori K; Nishikawa S; Xia Y; Karasawa K; Okamoto N; Oida K; Jang H; Matsuda H
Vet Immunol Immunopathol; 2011 Dec; 144(3-4):321-8. PubMed ID: 21908058
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of dogs undergoing surgical resection of mast cell tumors and soft tissue sarcomas: A prospective 2-year-long study.
Milovancev M; Townsend KL; Tuohy JL; Gorman E; Bracha S; Curran KM; Russell DS
Vet Surg; 2020 Jan; 49(1):96-105. PubMed ID: 31044443
[TBL] [Abstract][Full Text] [Related]
19. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
[TBL] [Abstract][Full Text] [Related]
20. Cryptic Epoxytiglianes from the Kernels of the Blushwood Tree (
Chianese G; Amin HIM; Maioli C; Reddell P; Parsons P; Cullen J; Johns J; Handoko H; Boyle G; Appendino G; Taglialatela-Scafati O; Gaeta S
J Nat Prod; 2022 Aug; 85(8):1959-1966. PubMed ID: 35973043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
